EUVIMEDEUVIMED entdecken
Open Access

Targeted Drug Delivery Using a Plug-to-Direct Antibody–Nanogel Conjugate

Uyen Huynh, Peidong Wu, Jingyi Qiu, Theeraphop Prachyathipsakul, Khushboo Singh, D Joseph Jerry, Jingjing Gao, S Thayumanavan iD

Biomacromolecules · 13.02.2023 · 24 (2) · 849-857

DOI: 10.1021/acs.biomac.2c01269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 13.01.2023. Verfasst von Uyen Huynh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted drug delivery using antibody-drug conjugates has attracted great attention due to its enhanced therapeutic efficacy compared to traditional chemotherapy. However, the development has been limited due to a low drug-to-antibody ratio and laborious linker-payload optimization. Herein, we present a simple and efficient strategy to combine the favorable features of polymeric nanocarriers with antibodies to generate an antibody-nanogel conjugate (ANC) platform for targeted delivery of cytotoxic agents. Our nanogels stably encapsulate several chemotherapeutic agents with a wide range of mechanisms of action and solubility. We showcase the targetability of ANCs and their selective killing of cancer cells over-expressing disease-relevant antigens such as human epidermal growth factor receptor 2, epidermal growth factor receptor, and tumor-specific mucin 1, which cover a broad range of breast cancer cell types while maintaining low to no toxicity to non-targeted cells. Overall, our system represents a versatile approach that could impact next-generation nanomedicine in antibody-targeted therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsImmunoconjugatesHumansNanogelsDrug Delivery SystemsCell Line, TumorPolyethylene GlycolsPolyethyleneimine

Substanzen

Antineoplastic AgentsNanogelsImmunoconjugatespolyethylene glycol polyethyleneimine nanogelPolyethylene GlycolsPolyethyleneimine

Autor:innen und Institutionen

  • Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States.
  • Department of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts 01003, United States.
  • Center for Bioactive Delivery, Institute for Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, United States.
  • Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, Massachusetts 01003, United States.

ORCID-Profile: S Thayumanavan

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Huynh, U., Wu, P., Qiu, J., Prachyathipsakul, T., Singh, K., Jerry, D. J., Gao, J., & Thayumanavan, S. (2023). Targeted Drug Delivery Using a Plug-to-Direct Antibody–Nanogel Conjugate. Biomacromolecules, 24(2), 849-857. https://doi.org/10.1021/acs.biomac.2c01269

Vancouver

Huynh U, Wu P, Qiu J, Prachyathipsakul T, Singh K, Jerry DJ, et al. Targeted Drug Delivery Using a Plug-to-Direct Antibody–Nanogel Conjugate. Biomacromolecules. 2023;24(2):849-857. doi:10.1021/acs.biomac.2c01269

BibTeX
@article{Huynh2023,
  author = {Huynh, Uyen and Wu, Peidong and Qiu, Jingyi and Prachyathipsakul, Theeraphop and Singh, Khushboo and Jerry, D Joseph and Gao, Jingjing and Thayumanavan, S},
  title = {Targeted Drug Delivery Using a Plug-to-Direct Antibody–Nanogel Conjugate},
  journal = {Biomacromolecules},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {849--857},
  doi = {10.1021/acs.biomac.2c01269}
}
Kostenlos starten →